神经肿瘤学脑脊液生物标志物发现与验证的实用指南
本文综述脑脊液作为胶质瘤液体活检来源的关键影响因素,包括采样部位与肿瘤解剖位置的关系、腰段与颅内脑脊液间肿瘤来源分析物的显著梯度,以及肿瘤-脑脊液接触和血脑屏障破坏等影像学协变量。文章还讨论经Ommaya储液囊等通路装置进行纵向颅内脑脊液采样的可行性及分析物产量、样本体积和手术切除动态效应带来的挑战,并给出基于作者集体经验的脑脊液胶质瘤生物标志物发现与验证要点与建议。
要点
- 腰段与颅内脑脊液腔室间肿瘤来源分析物存在显著梯度,采样部位选择至关重要
- 肿瘤-脑脊液接触和血脑屏障破坏可分别影响生物标志物检测和血浆来源分析物丰度
- 纵向颅内脑脊液采样可反映治疗反应和疾病进展,但分析物产量、样本体积和手术切除动态效应带来挑战
核心结论
- 脑脊液是胶质瘤生物标志物发现和验证的有价值液体活检来源,其分析物丰度受解剖、影像学和纵向因素即「时空连续体」影响,作者据此以「搭车客指南」形式提供要点与建议。
研究设计与样本
- 综述,评估影响胶质瘤脑脊液生物标志物丰度的解剖、影像学和纵向因素,并回顾纵向脑脊液生物样本库建设的实际操作考虑,包括通路装置放置与采集。
主要发现
- 腰段与颅内脑脊液腔室间肿瘤来源分析物存在显著梯度,凸显采样部位选择的重要性。
- 肿瘤-脑脊液接触和血脑屏障破坏是可能分别影响生物标志物检测和脑脊液中血浆来源分析物丰度的关键协变量。
- 经Ommaya储液囊等通路装置实现的纵向颅内脑脊液采样可能提供观察治疗反应和疾病进展的窗口,但分析物产量、样本体积的变异以及手术切除的动态效应带来挑战。
关键数值与推荐
- 原文未报告具体数值标准或推荐等级。
临床怎么用
- 作者基于集体经验提供脑脊液胶质瘤生物标志物发现与验证的要点与建议,并为拟在本机构开展脑脊液生物样本库建设的研究者提供资源。
局限性
- 分析物产量、样本体积存在变异,手术切除的动态效应带来挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cerebrospinal fluid (CSF) has emerged as a valuable liquid biopsy source for glioma biomarker discovery and validation. CSF produced within the ventricles circulates through the subarachnoid space, where the composition of glioma-derived analytes is influenced by the proximity and anatomical location of sampling relative to tumor, in addition to underlying tumor biology. The substantial gradients observed between lumbar and intracranial CSF compartments for tumor-derived analytes underscore the importance of sampling site selection. Moreover, radiographic features, such as tumor-CSF contact and blood-brain barrier disruption, are critical covariates that may affect biomarker detection and the abundance of plasma-derived analytes in CSF, respectively. Longitudinal intracranial CSF sampling, enabled by access devices like Ommaya reservoirs, may offer a window into treatment response and disease progression, though variability in analyte yield, sample volumes, and the dynamic effects of surgical resection pose challenges. This review critically evaluates the anatomic, radiographic, and longitudinal factors, or "time-space continuum," that impact glioma CSF biomarker abundance. Practical considerations for longitudinal CSF biobanking, including access device placement and collection, are also reviewed. Key takeaways and recommendations for CSF glioma biomarker discovery and validation are provided as a "hitchhiker's guide" based on our collective experience, along with resources for investigators aiming to develop CSF biobanking at their institutions.
引用
- Riviere-Cazaux C, Keough MB, Zuccato JA, et al. A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology. Neuro Oncol. 2025. PMID: 39786477. doi:10.1093/neuonc/noae276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。